The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

The incidence and risk for suicidality and self-harm were low for individuals given glucagon-like peptide-1 receptor agonists ...

Dr. Troy Mensen is a family medicine doctor based in the Chicago area. He completed his undergraduate degree at the University of Northern Iowa and his doctorate at Des Moines University College ...

Scientists have discovered a naturally occurring molecule that aids appetite control and weight loss so well, it may compete with popular GLP-1 agonists like Ozempic. It's called BRP (BRINP2-related ...

Could a diabetes drug slash your cancer risk? New research shows GLP-1 receptor agonists may protect patients with type 2 diabetes from deadly blood cancers—beyond just managing blood sugar.

One of the peptide products is glucagon-like peptide 1, or GLP-1, which regulates appetite and blood sugar levels; semaglutide works by mimicking the effect of GLP-1 in the body.